CURE OF PSEUDOMONAS AERUGINOSA INFECTION IN NEUTROPENIC PATIENTS BY CONTINUOUS INFUSION OF CEFTAZIDIME

The Lancet ◽  
1988 ◽  
Vol 331 (8591) ◽  
pp. 937 ◽  
Author(s):  
S. Daenen ◽  
H. de Vries-Hospers
Keyword(s):  
Pseudomonas Aeruginosa ◽  
Continuous Infusion ◽  
Neutropenic Patients ◽  
Pseudomonas Aeruginosa Infection

scholarly journals Outpatient therapy with piperacillin/tazobactam using elastomeric pumps in patients with Pseudomonas aeruginosa infection

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Jose Luis Lamas Ferreiro ◽  
Judith Álvarez Otero ◽  
Ana Sanjurjo Rivo ◽  
Lucía González González ◽  
Irene Rodríguez Conde ◽  
...  
Keyword(s):  
Pseudomonas Aeruginosa ◽  
Continuous Infusion ◽  
Antimicrobial Therapy ◽  
Clinical Cure Rate ◽  
Hospital Treatment ◽  
Cure Rate ◽  
End Of Treatment ◽  
Pseudomonas Aeruginosa Infection ◽  
The Cost ◽  
Theoretical Cost

AbstractThe aim of this study was to evaluate the efficacy and safety of outpatient antimicrobial therapy with piperacillin-tazobactam in continuous infusion using elastomeric pumps and to evaluate the economic impact compared with conventional hospital treatment in patients with Pseudomonas aeruginosa (PA) infections. This is an observational study. Patients with PA infection treated with continuous piperacillin-tazobactam infusion using elastomeric pumps in our hospital between January 2015 and December 2017 were included. Primary outcomes were mortality during antibiotic treatment and mortality at 30 days. Secondary outcomes were reinfection or relapse at 30 days and clinical cure rate. The cost of each episode was compared with theoretical cost of the same treatment using conventional hospitalization. 35 patients were included. One patient (2.9%) died during the treatment. Overall 30-day mortality was 5.7%. No death was related to infection by PA. One patient (2.9%) had a reinfection at 30 days. Cure was achieved in 93% of patients at the end of treatment. There were no severe complications related to elastomeric pumps. Treatment cost with outpatient antimicrobial therapy was 67% lower than theoretical cost with conventional hospital treatment. Oupatient antimicrobial therapy with piperacillin-tazobactam in continuous infusion using elastomeric pumps in patients with PA infections is safe and effective with lower costs.

The effect of the antiinflammatory IL-1R antagonist anakinra in mice with CF-like lung disease and Pseudomonas aeruginosa infection

Pneumologie ◽  
2016 ◽  
Vol 70 (07) ◽  
Author(s):  
A Schütte ◽  
Z Zhou-Suckow ◽  
J Schatterny ◽  
S Schmidt ◽  
S Hassel ◽  
...  
Keyword(s):  
Pseudomonas Aeruginosa ◽  
Lung Disease ◽  
Pseudomonas Aeruginosa Infection

scholarly journals Epidemiology of first/new Pseudomonas aeruginosa infection in cystic fibrosis patients

2010 ◽  
Vol 9 ◽  
pp. S29 ◽  
Author(s):  
L. Zavataro ◽  
G. Taccetti ◽  
L. Cariani ◽  
N. Ravenni ◽  
G. Braccini ◽  
...  
Keyword(s):  
Cystic Fibrosis ◽  
Pseudomonas Aeruginosa ◽  
Pseudomonas Aeruginosa Infection

scholarly journals Rapid evolution and host immunity drive the rise and fall of carbapenem resistance during an acute Pseudomonas aeruginosa infection

2021 ◽  
Vol 12 (1) ◽  
Author(s):  
Rachel Wheatley ◽  
Julio Diaz Caballero ◽  
Natalia Kapel ◽  
Fien H. R. de Winter ◽  
Pramod Jangir ◽  
...  
Keyword(s):  
Pseudomonas Aeruginosa ◽  
Efflux Pump ◽  
Rapid Evolution ◽  
Carbapenem Resistance ◽  
Host Immunity ◽  
High Definition ◽  
Loss Of Resistance ◽  
Pseudomonas Aeruginosa Infection ◽  
Second Wave

AbstractIt is well established that antibiotic treatment selects for resistance, but the dynamics of this process during infections are poorly understood. Here we map the responses of Pseudomonas aeruginosa to treatment in high definition during a lung infection of a single ICU patient. Host immunity and antibiotic therapy with meropenem suppressed P. aeruginosa, but a second wave of infection emerged due to the growth of oprD and wbpM meropenem resistant mutants that evolved in situ. Selection then led to a loss of resistance by decreasing the prevalence of low fitness oprD mutants, increasing the frequency of high fitness mutants lacking the MexAB-OprM efflux pump, and decreasing the copy number of a multidrug resistance plasmid. Ultimately, host immunity suppressed wbpM mutants with high meropenem resistance and fitness. Our study highlights how natural selection and host immunity interact to drive both the rapid rise, and fall, of resistance during infection.

Sign in / Sign up

Export Citation Format

Share Document